Semin Reprod Med 2018; 36(05): 265-272
DOI: 10.1055/s-0038-1676849
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Human Reproductive Cell Cryopreservation, Storage, Handling, and Transport: Risks and Risk Management

Mina Alikani
1   Northwell Health Fertility Laboratories, New York, New York
,
Lodovico Parmegiani
2   Reproductive Medicine Unit, GynePro Medical Centers, Bologna, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
04. April 2019 (online)

Preview

Abstract

Millions of human oocytes and embryos are stored in thousands of locations across the globe. This inventory continues to grow as cryopreservation becomes more successful and more widely applied. The results of studies assessing pregnancy and neonatal outcomes following frozen embryo transfer (FET) have been encouraging, showing lower incidences of small for gestational age neonates and preterm birth compared with fresh transfers. However, many of these studies have also shown that the odds of large for gestational age births and macrosomia are higher after FET. The origin of these conditions remains unclear. Cryostorage presents many potential risks to the cryopreserved cells/tissues, including loss of viability and contamination, but risks are faced also by care providers—for example, injury and financial liability—and by patients—for example, accidental loss of their reproductive tissues, the burden of embryos they no longer wish to use and failing to meet their contractual obligations. Studies are urgently needed to explore and understand all dimensions of cryostorage to help ART clinics develop effective strategies to manage associated risks. The future of cryostorage, as for many other areas of ART and medicine, is automation.